H.C. Wainwright analyst Brandon Folkes initiated coverage of Traws Pharma with a Buy rating and $8 price target. The company's pipeline is led by two oral antivirals, ratutrelvir in development for COVID-19, and tivoxavir marboxil for seasonal and avian influenza, the analyst tells investors in a research note. The firm believes Traws has the potential to unlock value for shareholders if the company is able to replicate the strong early stage data.
